Chinese Doctors at Coronavirus Hub Say Evidence on Chloroquine Is Inconclusive

One doctor sees promise for Kaletra—an antiretroviral drug for HIV—even though a recent study concluded it didn’t work

Dr. Zhang Dingyu, left, spoke Thursday in Wuhan about his hospital’s experience with hundreds of coronavirus cases. PHOTO: QIANWEI ZHANG/THE WALL STREET JOURNAL
Dr. Zhang Dingyu, left, spoke Thursday in Wuhan about his hospital’s experience with hundreds of coronavirus cases. PHOTO: QIANWEI ZHANG/THE WALL STREET JOURNAL

Chinese doctors who have for months treated patients on the front lines of China’s fight against the new coronavirus offered a sobering assessment of the potential treatments, saying they hadn’t seen clear evidence that drugs such as chloroquine were effective.

One doctor, however, said he saw some promise for Kaletra—an antiretroviral drug for HIV.

In hospital interviews arranged Thursday by government authorities in Wuhan, the central Chinese city of 11 million where the new coronavirus crisis erupted late last year, doctors called for further research into the use of chloroquine, an anti-malarial drug.

The doctors also cautioned that some recovered patients had tested positive again, while expressing concern about asymptomatic cases, dozens of which have been disclosed in recent days across China.

The doctors’ assessments came one day after Chinese authorities eased their lockdown of Wuhan, and as the U.S. braces in the coming days for what is expected to be the worst of its surge in infections.

Chloroquine has been the subject of fierce debate within the U.S. administration. President Trump has at times touted it as a remedy and in recent days he has advised even those without symptoms to take the drug. That has come in defiance of advice from public health experts and some of his own medical advisors.

White House trade advisor Peter Navarro has cited a study from Wuhan, among other evidence, to argue for the federal government to distribute its stockpile of one form of the drug—hydroxychloroquine—to hard-hit areas of the U.S.

Zhang Dingyu, the head of Wuhan’s Jinyintan Hospital, which has handled hundreds of coronavirus cases since December, said the evidence on chloroquine was so far inconclusive.

“Some patients took it by themselves, and after taking it, there were good and bad” results, Dr. Zhang said Thursday, adding that some patients hadn’t tested negative even seven to 10 days after taking the drug. “There’s no scientific conclusion.”

He expressed concern too about the drug’s recommended dosage. Local health authorities warned in February that an overdose of chloroquine could be fatal.

At the peak of the epidemic in Wuhan, Dr. Zhang said Jinyintan Hospital was treating as many as 500 patients. It still has 123 patients, of which three were in serious condition on Thursday. None were in intensive care, he said.

While Dr. Zhang expressed uncertainty about chloroquine, he said Kaletra —a drug made by U.S. pharmaceutical giant AbbVie Inc. that blocks the enzymes some viruses need to replicate—appeared to have been effective with patients and infected colleagues, even though a recent study concluded it didn’t work.

Desperation and the lack of a proven cure have prompted doctors around the world to experiment with remedies that haven’t yet passed clinical trials.

On Feb. 18, China’s National Health Commission added chloroquine phosphate—one common form of the drug—to a list of officially approved treatments for coronavirus patients, though clinical trials haven’t yet finished.

The U.S. Food and Drug Administration on March 28 authorized the emergency use of chloroquine phosphate and hydroxychloroquine in hospitalized coronavirus patients who weren’t able to participate in a clinical trial. That allowed the government to distribute millions of doses donated by drug companies.

Zhang Junjian, a doctor who ran a field hospital in Wuhan that treated more than 1,700 coronavirus cases, said in a separate group interview on Thursday that 20 to 30 patients had been treated with chloroquine—with the patients’ permission—but it was unclear if the drug was effective.

Given the drug’s unproven effects, “we were extremely careful,” said Dr. Zhang, who is vice president of Wuhan’s Zhongnan hospital, another institution that treated thousands of coronavirus cases. “You can’t see any difference between it and other treatments.”

Dr. Zhang, the Jinyintan Hospital chief, said that several of his patients—and three of his infected colleagues—had taken Kaletra.

“After taking it, the changes in their entire lungs were really dramatic,” he said, adding that none of them needed critical care. “If I had a chance to do things again, I would definitely have patients take this drug within three to five days of getting sick.”

A study published last month in the New England Journal of Medicine, based on a test on severe coronavirus cases at Jinyintan, concluded that Kaletra wasn’t effective. But Jinyintan’s Dr. Zhang said supplementary data in the study suggested it had potential.

Many of the cases at Jinyintan took Kaletra in conjunction with bismuth subcitrate potassium, which had also been effective, he said. Bismuth subcitrate is used in combination with other drugs to treat a common bacterial stomach infection.

Dr. Zhang of Jinyintan also recommended convalescent plasma treatment, which involves transfusing blood plasma from someone who has recovered from the coronavirus into someone who is sick with the virus, in hopes that the donor’s antibodies help the recipient recover.

The FDA says the treatment hasn’t yet been shown to be safe and effective for Covid-19, the disease caused by the coronavirus, but the agency approved its emergency use on a case-by-case basis in March and issued broader recommendations on its use and study on Wednesday.

The Chinese doctors said that 34 of their patients had tested positive again after recovering and being discharged, but they suspected that was because of flawed tests giving false negative results, rather than the patients having been reinfected.

They also both said they didn’t expect a big second wave of infections in China, although they allowed that smaller outbreaks in certain locations were still possible.

Most worrying was a small number of patients—still in hospitals—who had been infected for several weeks, including several for more than 60 days, said Dr. Zhang of Jinyintan. Another focus of concern, he said, was the number of asymptomatic cases and their level of  infectiousness.

“This virus may be with mankind for a long time, so what we need to work on is how to take the next steps,” he said. “We used to pay attention to the flu, AIDS and hand, foot and mouth disease. Now we may need a special ward for this.”

Zhongnan’s Dr. Zhang said his field hospital, in a converted exhibition center, had been closed due to the winddown in the number of cases. But he cautioned that it would not be dismantled for some time—a reflection of lingering concern around how the pandemic will develop in Wuhan in the coming weeks.

Bình luận

Xin vui lòng gõ tiếng Việt có dấu

Các tin khác

Vietnam's Export Sector Poised for Growth in 2025

Vietnam's Export Sector Poised for Growth in 2025

(SGI) - As 2024 closes on a high note for Vietnam’s export industry, the achievements of the past year provide a strong foundation for continued growth in 2025. With a record-setting export turnover and promising developments across multiple sectors, Vietnam’s economy is poised to remain competitive on the global stage. However, challenges persist, requiring adaptability and innovation from businesses and policymakers alike.

No Black Swans in 2025

No Black Swans in 2025

(SGI) - As 2024 comes to a close, investors are speculating about the future of Vietnam’s stock market. Will the VN-Index face sharp declines, or will it offer opportunities for growth? Saigon Investment sat down with NGUYỄN VIỆT ĐỨC, Digital Business Director at VPBank Securities, to explore the risks and opportunities in 2025.

2025: A Year of Cautious Economic Recovery for Vietnam

2025: A Year of Cautious Economic Recovery for Vietnam

(SGI) - The robust performance of the U.S. economy was a key driver of Vietnam’s GDP growth in 2024. This dynamic is expected to continue shaping Vietnam’s economy in 2025, as the U.S. remains Vietnam’s largest export market. However, challenges lie ahead, with potential trade tensions, shifting global demands, and domestic economic factors requiring careful navigation.

Vietnam's 2025 GDP Target of 8%: A Bold and Challenging Goal

Vietnam's 2025 GDP Target of 8%: A Bold and Challenging Goal

(SGI) - Vietnam’s National Assembly recently approved a resolution targeting an economic growth rate of 6.5–7% for 2025 as part of its socio-economic development plan. However, in a recent directive, the Prime Minister raised the bar, setting a more ambitious target of 8%.

2025: Vietnam’s Strategic Opportunities with Major Nations

2025: Vietnam’s Strategic Opportunities with Major Nations

(SGI) - As we step into 2025, Vietnam’s economy finds itself at a critical juncture, fueled by its burgeoning partnerships with global powers. On this occasion, Saigon Investment sat down with Minister of Industry and Trade, Mr. NGUYỄN HỒNG DIÊN, to discuss the strategic opportunities these comprehensive partnerships offer Vietnam.

A Tragic Chapter for VNDirect

A Tragic Chapter for VNDirect

(SGI) - VNDirect Securities Corporation (VND) has found itself in a challenging position in recent months, suffering a severe decline in both its brokerage market share and profits.

The Rise of the USD and Tech Stocks in 2024

The Rise of the USD and Tech Stocks in 2024

The year 2024 has proven to be a monumental one for financial markets, marked by a series of unprecedented highs in key assets such as gold, US stocks, and Bitcoin. While these records highlight the robust dynamics of global markets, they also reveal the complexities and challenges investors face in navigating these evolving landscapes.

Igniting New Growth Drivers

Igniting New Growth Drivers

(SGI) - Vietnam’s pursuit of sustainable economic growth demands the creation of new growth drivers, prominently underpinned by science, technology, innovation (STI), and digital transformation (DT). However, the nation’s current investment in these areas is just a quarter of the global average, and institutional frameworks remain insufficient to support their robust development.

The Banking Race for Customers

The Banking Race for Customers

(SGI) - As of early December 2024, the total outstanding credit balance of the Vietnamese banking system reached a staggering VND 15.3 quadrillion, surpassing the total mobilised capital of VND 14.8 quadrillion.

Participants at the Vietnam Circular Economy Forum 2024 in Hanoi on December 10.__Photo: vneconomy.vn

UNDP to support Vietnam on path toward circular economy

(SGI) - The UN Development Program (UNDP) is willing to support Vietnam in conducting reforms to create an ecosystem to facilitate the transition to a greener circular and low-carbon economy, towards sustainable development, Resident Representative of UNDP in Vietnam Ramla Khalidi stated at the Vietnam Circular Economy Forum 2024 in Hanoi on December 10.

A Broader Vision for Vietnam’s Future

A Broader Vision for Vietnam’s Future

(SGI) - At the 15th National Assembly session, General Secretary Tô Lâm highlighted a critical concern: "Seeing the world's rapid development makes me impatient. Vietnam cannot afford to lag behind developed nations." Despite its impressive growth in recent years, Vietnam faces significant risks, including falling into the middle-income trap and struggling to keep pace with the global economy.

Streamlining the State Apparatus for Efficiency and Effectiveness

Streamlining the State Apparatus for Efficiency and Effectiveness

Reforming Vietnam's state administrative apparatus has long been a critical focus of the Communist Party. The goal is to create a streamlined, effective, and efficient system that better serves the state, enterprises, and citizens. Achieving this requires not only structural changes but also a shift in mindset and governance approaches.

Despite Record Profits, Bad Debt Looms as a Concern for Banks

Despite Record Profits, Bad Debt Looms as a Concern for Banks

(SGI) - The Vietnamese banking sector recently unveiled its financial performance for the third quarter of 2024, revealing impressive profit growth across the board. However, beneath these glowing figures lies a mounting issue: the sharp increase in bad debts. This duality has sparked discussions about the sustainability of these profits and the health of the banking system.

DIC Corp Struggles to Regain Momentum

DIC Corp Struggles to Regain Momentum

(SGI) - DIC Corp, formally known as the Construction Development Investment Joint Stock Corporation (DIG), has recently encountered significant turbulence. This has led major securities firms to temporarily halt valuations and recommendations for its DIG shares, citing the company’s current struggles and looming risks.

Banks Struggle to Balance Capital Amid Rising Lending Demands

Banks Struggle to Balance Capital Amid Rising Lending Demands

(SGI) - Vietnam’s banking sector is grappling with a persistent challenge: a widening gap between capital mobilization and lending. While banks often turn to charter capital to bridge this shortfall, experts warn that this imbalance exerts upward pressure on interest rates and poses significant risks to the financial system.

SBV must strengthen credit management so that Vietnam can respond swiftly and effectively to any changes in the global economic climate__Photo: VNA

SBV asked to strengthen credit management this year

(SGI) - The Premier on November 27 signed Official Telegraph 122/CD-TTg, requesting the Governor of the State Bank of Vietnam (SBV) to outline solutions aimed at improving credit management for 2024 in the face of evolving global economic challenges.

WB Vice President for East Asia and the Pacific Manuela V. Ferro (Photo: VNA)

Vietnam - a success story in development path: WB Vice President

(SGI) - World Bank (WB) Vice President for East Asia and the Pacific Manuela V. Ferro described Vietnam as a success story in terms of economic development since it has dramatically transformed the economic landscape, achieving the extraordinary feat of increasing family incomes sixfold while attracting significant foreign investment over the past 40 years.

U.S. President Donald Trump arrives aboard Air Force One at Noi Bai International Airport in Hanoi, Vietnam November 11, 2017.

Vietnam's Gains and Losses with America's New Policies

(SGI) - With the conclusion of the U.S. Presidential election, all eyes are on the incoming administration of Donald Trump, set to officially begin in early 2025. Across the globe, many countries are anxious about how this transition might impact their economies. For Vietnam, the stakes are high, with both opportunities and challenges emerging from the possible shift in U.S. trade and economic policies.